Sepsis-associated cardiovascular dysfunction is one of the main causes of mortality in critically ill patients. PTP1B is negative regulator of insulin signaling and endothelial Nitric Oxide (NO) production, two mechanisms likely involved in the pathogenesis of sepsis. We recently showed that gene deletion or pharmacological inhibition of PTP1B improves endothelial dysfunction and reduces the severity of heart failure. The aim of the present study was to assess the effect of PTP1B gene deletion on lipopolysaccharide (LPS)-induced cardiovascular dysfunction and mortality in mice. PTP1B-/-or wild-type (WT) mice received LPS (15mg/kg) or vehicle followed by subcutaneous saline resuscitation (30ml/kg). LPS significantly enhanced cardiac and arterial PTP1B mRNA expression. Compared with WT, PTP1B-/-mice displayed markedly reduced mortality (Survival 4 days after LPS: WT: 0%; PTP1B-/-70%, p<0.01), associated with a higher locomotor activity. Evaluation of vascular function 8h after LPS in isolated mesenteric resistance arteries (arteriograph system) showed that PTP1B-/-LPS mice had improved contractile response to phenylephrine, and restored flow mediated, NO dependentdilatation (% dilatation to 200μl/min: WT 6,3±3; PTP1B-/-16,5±2, p<0.05) associated with significant increases in phosphorylation of Akt and eNOS, and reduced mRNA expression of VCAM-1, ICAM-1, COX-2, IL-1β, iNOS and Gp91phox (PCR). Evaluation of left ventricular (LV) function by echocardiography, and pressurevolume curves 8h after LPS revealed reduced cardiac dysfunction in PTP1B-/-mice as shown by an increased LV fractional shortening (WT 17,3±1; PTP1B-/-24±1, p<0.05) and LV end systolic pressure-volume relation (WT 16±2; PTP1B-/-20±2, p<0.05) together with reduced LV end diastolic pressure-volume relation (WT 4,7±1,7; PTP1B-/-2.4±0.9 mmHg/RVU, p<0.05). Improved cardiac contractility was also observed ex-vivo in hearts isolated and perfused 8h after LPS (LV Developed Pressure: WT 25±5; PTP1B-/-50±5 mmHg, p<0.05). Improved cardiac function was associated with significant decreases in myocardial markers of inflammation and oxidative stress (VCAM-1, ICAM-1, CD45, IL-1β, TNF-α and Gp91phox), reduced P38 and ERK1/2 phosphorylation and limited decrease of phospholamban phosphorylation (WT -42%; PTP1B-/--22.8, p<0.05). Thus, we demonstrate for the first time that PTP1B gene deletion protects against lipopolysaccharide-induced cardiovascular dysfunction and mortality. These results suggest that PTP1B is an attractive target for the treatment of sepsis. Purpose: High glucose-induced endothelial dysfunction is partially mediated by the down-stream pathophysiological effects triggered by increased expression of Endothelin-1 (ET-1). The molecular control mechanisms of ET-1 synthesis are yet to be discovered. Members of the CCAAT/Enhancer-Binding Proteins (C/EBP) family are important regulators of key metabolic processes, cellular differentiation and proinflammatory genes. In this study, we aimed at elucidating the role of C/EBP in mediating the high glucose effect on ET-1 expression in human endothelial cells.
Purpose: High glucose-induced endothelial dysfunction is partially mediated by the down-stream pathophysiological effects triggered by increased expression of Endothelin-1 (ET-1). The molecular control mechanisms of ET-1 synthesis are yet to be discovered. Members of the CCAAT/Enhancer-Binding Proteins (C/EBP) family are important regulators of key metabolic processes, cellular differentiation and proinflammatory genes. In this study, we aimed at elucidating the role of C/EBP in mediating the high glucose effect on ET-1 expression in human endothelial cells.
Methods and results:
Human umbilical vein cells (EAhy926) and primary cultures of human aortic Endothelial Cells (EC) were exposed to high levels of glucose (16.5-25 mM). Real-time PCR, Enzyme-Linked Immunosorbent Assay (ELISA), Western blot, ET-1 promoter-luciferase reporter analysis, and chromatin immunoprecipitation assays were employed to investigate ET-1 regulation. The expression various C/EBP isoforms was selectively downregulated by siRNAmediated gene silencing. High glucose dose-dependently induced activation and expression of C/EBPα, C/EBPβ, and C/EBPδ. It also induced significant increases in ET-1 gene and peptide expression. Silencing of C/EBPα, C/EBPβ or C/EBPδ reduced significantly the high glucose-induced upregulation of ET-1 mRNA, prepro ET-1, and ET-1 secretion. Chemical inhibition of JNK, p38MAPK and ERK1/2 diminished significantly the high glucose-induced nuclear translocation of C/EBP and ET-1 expression. In silico analysis indicated the existence of typical C/EBP within human ET-1 gene promoter. Transient overexpression of C/EBPα, C/EBPβ or C/EBPδ upregulated the luciferase level controlled by the ET-1 gene promoter. The direct interaction of C/EBPα, C/EBPβ or C/EBPδ proteins with the ET-1 promoter in high glucose-exposed EC was confirmed by chromatin immunoprecipitation assay. Conclusions: High glucose-induced ET-1 expression is mediated via multiple mechanisms. We present evidence that members of the C/EBP proinflammatory transcription factors are important regulators of ET-1 in high glucose-exposed human endothelial cells. High glucose-induced activation of C/EBP-related signaling pathways may induce excessive ET-1 synthesis, thus promoting dysfunction of the vascular wall cells in diabetes.
